Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study
单位:[1]Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[2]Department of Cardiology, Da Qing First Hospital, Da Qing, China.[3]Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.[4]Division of Non-Communicable Disease Control and Community Health, Chinese Center for Disease Control and Prevention, Beijing, China.
Background We aimed to explore if hyperglycaemia and hyperinsulinemia in the diabetes and prediabetes population were associated with increased risk of cancer occurence. Methods Overall, 1700 participants with different glycaemic statuses were screened from the 110,660 residents of Da-Qing, China, in 1985. They were followed up to 30 years to access cancer outcomes. Results Cancer was identified in 15.2% (259/1700) of the participants. The incidence of cancer in the normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and diabetes groups was 6.06, 6.77, and 7.18 per 1000 person-years, respectively (P = 0.02). In the Fine-Gray model with all cause death as competing risk, compared with the NGT controls, both IGT and diabetes groups demonstrated significantly higher risk of cancer (for the IGT group, adjusted hazard ratio (aHR) = 1.77, 95% CI 1.38-2.27, P < 0.0001; for the diabetes, aHR = 3.34, 95% CI 2.64-4.22, P < 0.0001). Among the IGT participants, progress to diabetes (aHR = 2.28, 95%CI 1.24-4.20, P = 0.008) and insulin-area under the curve at baseline (for 1 SD increase, aHR = 1.39, P = 0.02) were also associated with the risk of cancer after adjustment of covariables. Conclusions Hyperglycaemia in patients with diabetes, hyperinsulinemia, and progression to diabetes in people with IGT is significantly associated with the long-term increased risk of cancer occurrence.
基金:
This study was supported during 1986–1992 by the World Bank, the Ministry of Public
Health of the People’s Republic of China, and Da Qing First Hospital; during
2004–2009 by CDC/WHO Cooperative Agreement No. U58/CCU424123-01-02, the
China-Japan Friendship Hospital, and Da Qing First Hospital; and during 2015–2018
by CDC/Chinese CDC Cooperative Agreement No. 5U19GH000636-05, the National
Center of Cardiology & Fuwai Hospital, China-Japan Friendship Hospital, and Da Qing
First Hospital, in 2020 by Chinese Academy of Medical Sciences, Innovation Fund for
Medical Sciences (grant number: 2020-I2M-2-006).
第一作者单位:[1]Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
通讯作者:
通讯机构:[1]Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.[3]Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
推荐引用方式(GB/T 7714):
He Siyao,Wang Jinping,Shen Xiaoxia,et al.Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study[J].BRITISH JOURNAL of CANCER.2022,127(1):102-108.doi:10.1038/s41416-022-01758-x.
APA:
He, Siyao,Wang, Jinping,Shen, Xiaoxia,Qian, Xin,An, Yali...&Li, Guangwei.(2022).Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study.BRITISH JOURNAL of CANCER,127,(1)
MLA:
He, Siyao,et al."Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study".BRITISH JOURNAL of CANCER 127..1(2022):102-108